GLIPR2

Across TCGA pan-cancer cohorts, GLIPR2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GLIPR2 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GLIPR2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLIPR2 expression acts as an unfavorable survival marker.

HNSC and PRAD are the cancer types where GLIPR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.156	0.685	.009	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GLIPR2–HNSC (DFS)

Open the HNSC breakdown →